Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Co-Stone Capital

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 106
Average round size
info
The average size of a deal this fund participated in
$50M
Portfolio companies 96
Rounds per year 4.61
Lead investments 14
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.09
Exits 7
Key employees Soon

Areas of investment

  • Manufacturing
  • Semiconductor
  • Artificial Intelligence
  • Hardware
  • Health Care
Summary

The fund is constantly included in 2-6 investment rounds annually. Considering the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations. When the investment is from Co-Stone Capital the average startup value is 500 millions - 1 billion dollars. The high activity for fund was in 2018. Deals in the range of 50 - 100 millions dollars are the general things for fund.

Among the most successful fund investment fields, there are Artificial Intelligence, Digital Media. Among the most popular portfolio startups of the fund, we may highlight SenseTime, Chuchujie, Carzone. The fund has no exact preference in some founders of portfolio startups. Besides, a startup needs to be aged 6-10 years to get the investment from the fund.

The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Co-Stone Capital, startups are often financed by Hejun Capital, Tencent Holdings, Matrix Partners China. The meaningful sponsors for the fund in investment in the same round are Green Pine Capital Partners, Fortune Capital, CICC. In the next rounds fund is usually obtained by Vinno Capital, ZSVC, Tiger Global Management.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Co-Stone Capital:
Typical Co-investors
Co-Stone Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Co-Stone Capital:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Onco Technology

Manufacturing
Semiconductor
$15M31 Jan 2024 Shenzhen, Guangdong, China

Aixin Semiconductor Technology

Manufacturing
Semiconductor
Test and Measurement
25 Jan 2024 Guangdong, Tianjin, China

Pinzhou Technology

Advanced Materials
Manufacturing
$15M29 Dec 2023 Shanghai, Shanghai, China

Yitu Technology

Automotive
20 Dec 2023 Shenzhen, Guangdong, China

Panacro

Clinical Trials
Pharmaceutical
Professional Services
$15M18 Dec 2023 Hefei, Anhui, China

Zhiyuan Robotics

Artificial Intelligence
Manufacturing
Robotics
$92M14 Dec 2023 Shanghai, Shanghai, China

Panther Technology

Advanced Materials
Manufacturing
Semiconductor
01 Dec 2023 Shenzhen, Guangdong, China

Rongna New Energy

Advanced Materials
Battery
Manufacturing
10 Nov 2023 Guangdong, Tianjin, China

Sonosemi Medical

Health Diagnostics
Manufacturing
Medical Device
$30M26 Oct 2023 Shenzhen, Guangdong, China
News
IASO Biotherapeutics Secures $108 Million Series C Funding to Advance Global Development of Innovative Cell Therapies

– IASO Biotherapeutics announced the completion of $108m Series C to advance the global development of novel cell therapies and biologics for oncology and autoimmune diseases.
– The round was led by CDH Baifu, and followed by CCB International, with strong participation from Everbright Limited, Co-Stone Capital, CNCB Capital and Plaisance Capital.
– Current shareholder GL Ventures also participated.
– Since its founding in 2017, IASO Bio has raised more than $178m.
– Proceeds from the financing will be used to accelerate the global development and regulatory submissions of multiple novel cell therapies.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Co-Stone Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 106
Average round size 50M
Rounds per year 4.61
Peak activity year 2023
Lead investments 14
Follow on index 0.09
Exits 7
Group Appearance index 0.91

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Onco Technology

Manufacturing
Semiconductor
$15M31 Jan 2024 Shenzhen, Guangdong, China

Aixin Semiconductor Technology

Manufacturing
Semiconductor
Test and Measurement
25 Jan 2024 Guangdong, Tianjin, China

Pinzhou Technology

Advanced Materials
Manufacturing
$15M29 Dec 2023 Shanghai, Shanghai, China

Yitu Technology

Automotive
20 Dec 2023 Shenzhen, Guangdong, China

Panacro

Clinical Trials
Pharmaceutical
Professional Services
$15M18 Dec 2023 Hefei, Anhui, China

Zhiyuan Robotics

Artificial Intelligence
Manufacturing
Robotics
$92M14 Dec 2023 Shanghai, Shanghai, China

Panther Technology

Advanced Materials
Manufacturing
Semiconductor
01 Dec 2023 Shenzhen, Guangdong, China

Rongna New Energy

Advanced Materials
Battery
Manufacturing
10 Nov 2023 Guangdong, Tianjin, China

Sonosemi Medical

Health Diagnostics
Manufacturing
Medical Device
$30M26 Oct 2023 Shenzhen, Guangdong, China
Crunchbase icon

Content report

The following text will be sent to our editors: